A submicron structure includes a silica body defining a plurality of pores that are suitable to receive molecules therein, the silica body further defining an outer surface between pore openings of said plurality of pores; and a plurality of anionic molecules attached to the outer surface of the silica body. The anionic molecules provide hydrophilicity to the submicron structure and are suitable to provide repulsion between other similar submicron structures, and the submicron structure has a maximum dimension less than one micron.

A human lung cancer marker N3G4, and use of the same as human lung cancer marker is disclosed. Hybridoma cells which produce anti-N3G4 monoclonal antibodies, and the secreted monoclonal antibody LC128, and use of LC128 for the preparation of a diagnostic agent for lung cancer are also disclosed. Kits for in vitro diagnosis comprising the monoclonal antibody LC128 and methods for detecting tumor markers in lung tissue by using the monoclonal antibody LC128 are also disclosed.

Aspects of the disclosure relate to methods and compositions useful for in vivo and/or in vitro enzyme profiling. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. In some embodiments, the disclosure provides compositions and in vitro methods for localization of enzymatic activity in a tissue sample.

Methods and compositions are provided for objectively characterizing a pathological lesion in a patient. The method comprises: introducing into the patient a contrast enhancing agent; subjecting the patient to magnetic resonance imaging to obtain an image; and applying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum. The method may further comprise comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for the pathological lesion. In one example, the methods and compositions may be useful for identifying and objectively characterizing amyloid plaque deposits characteristic of Alzheimer's Disease.

The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.

The present disclosure relates to a nano complex material, a drug carrier including the same, a contract agent including the same, and a method for preparing the nano complex material, and the nano complex material of the present disclosure consists of a support and ionic particles and thus can exhibit excellent light absorbance, magnetic absorbance, storage stability, functionality as a contrast agent, and drug delivery performance, as well as low cytotoxicity.

The present invention relates to a biocompatible nanoparticle and a use thereof and, more specifically, to a biocompatible nanoparticle formed by irradiation an electron beam to an aqueous solution comprising at least one substance selected from the group consisting of a polysaccharide, a derivative thereof and a polyethylene glycol, thereby inducing inter-molecular cross-linking or intra-molecular cross-linking, and to a use of the biocompatible nanoparticle in a drug carrier, a contrast agent, a diagnostic agent or an intestinal adhesion prevention agent or for disease prevention and treatment.

Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying accessible proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.

A bionanofluid includes a carbon-based nanomaterial substantially mono-dispersed in a fluid. The carbon-based nanomaterial is surface modified with a polar group when the fluid is polar or with a non-polar group when the fluid is non-polar, and functionalized with a biological targeting moiety to allow specific association of the carbon-based nanomaterial to a targeted entity. A hybrid bionanofluid includes the bionanofluid, with the carbon-based nanomaterial further modified with a hybrid nanoparticle which includes an alloy, transition metal, semi-conductor, semi-metal or polymer based nanoparticle with biological targeting moiety. A hydrogel, foam, cream, spray or dried product includes the bionanofluid or hybrid bionanofluid. The bionanofluid or hybrid bionanofluid are useful in multimodal imaging (photo-luminescence, luminescence, photo-acoustic, MRI, ultrasound) and/or cellular targeting.

Lipid-based nanoparticle compositions are provided. The compositions generally comprise lipid-hydrophilic polymer-amyloid binding ligand conjugates, and may be liposomal compositions. The compositions, including the liposomal compositions, may be useful for imaging and/or the treatment of amyloid- plaque deposits characteristic of Alzheimer's Disease.